



Premiere Peptide Solutions

DATA SHEET

Product Name:	Alpha Synuclein Preformed Fibrils
Catalog #:	ASF-1001
Source:	Recombinant. A DNA sequence encoding the human alpha-synuclein (1-140) sequence was expressed in <i>E. coli</i> and was then made into preformed fibrils.
Estimated Size:	50nm-200nm
Monomer Sequence:	MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTQ EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA
Protein Purity:	>95% by SDS-PAGE
Counter Ion:	200mM Tris-HCl, 250mM NaCl pH 7.4
Supplied As:	Liquid
Storage:	-80°C
Description:	These preformed fibrils of α -synuclein may be used as a model for the pathogenic form of α -synuclein in numerous neuropathies. Sourced from <i>E. coli</i> , α -synuclein fibrils were prepared and confirmed by thioflavin assay and electron microscopy. The fibrils can be used for either <i>in vitro</i> requirements such as fibril stability, drug design, aggregation studies, or treatment models. Applications for <i>in vivo</i> experiments include <i>in vivo</i> seeding experiments and preformed fibril injections. The use of these preformed fibrils for <i>in vivo</i> can be advantageous, due to the level of α -synuclein fibrils being more physiological than viral-based or transgenic methods. Alpha synuclein preformed fibrils may also be used in the study of Parkinson's Disease or Lewy Body Dementia.
References:	1) Li J. et al. (2004). Rifampicin inhibits α -synuclein fibrillation and disaggregates fibrils. <i>Chemistry & Biology Volume 11</i> , Issue 11, 1513-1521. 2) Okuzumi, A. et al. (2018). Rapid dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment. <i>Acta Neuropathol Commun</i> 6, 96 https://doi.org/10.1186/s40478-018-0587-0

Not for human use, for research purposes only

www.rpeptide.com

1050 Barber Creek Bldg 300 Suite 103 • Watkinsville • Georgia • 30677 • USA
Tel 678-753-0747 • Fax 678-753-0746 • E-mail sales@rpeptide.com